Catafix

• Treatment and support of ocular surface disorders involving impaired cellular metabolism and oxidative stress, including:
• Moderate to severe Dry Eye Syndrome
• Corneal epithelial injuries and erosions (post-surgical or traumatic)
• Non-infectious keratitis and conjunctivitis with metabolic dysfunction
• Adjunct therapy in retinal ischemic conditions and optic neuropathies (off-label but clinically accepted)
• Supportive treatment for diabetic retinopathy and glaucoma to potentially reduce progression

• Adults: Instill 1–2 drops into the affected eye(s) 3–4 times daily. Maximum 6 times daily.
• Pediatrics: Use with caution; typically 1 drop 2–3 times daily in children over 2 years.
• Elderly: No dose adjustment needed; monitor for ocular dryness.
• Special populations: No dose adjustments for renal or hepatic impairment.
• Administration: Topical ophthalmic use only. Avoid contamination of the dropper tip. Separate from other eye drops by 5–10 minutes.

This combination enhances ocular cellular metabolism and protects against oxidative damage by supporting mitochondrial function. Adenosine activates purinergic receptors improving microcirculation and cell repair. Cytochrome-C facilitates electron transport in mitochondria, boosting ATP production. Sodium Succinate feeds the Krebs cycle, further enhancing oxidative phosphorylation. Nicotinamide replenishes NAD+ pools, vital for cellular redox balance and DNA repair. Together, these actions promote corneal healing, reduce inflammation, and protect retinal cells from ischemic damage.

• Absorption: Minimal systemic absorption due to topical administration.
• Distribution: Localized to ocular surface and anterior segment tissues.
• Metabolism: Metabolized intracellularly in ocular cells through normal mitochondrial pathways.
• Excretion: Eliminated locally via tear drainage and ocular metabolism.
• Onset: Clinical effects generally noted within days.
• Half-life: Not precisely established; rapid local metabolism.

• Pregnancy: No established FDA category; limited data. Use only if benefits outweigh risks.
• Lactation: Minimal expected systemic exposure; presumed safe with caution.
• Note: Data are limited; monitor closely if used during pregnancy or breastfeeding.

• Ophthalmic metabolic enhancer and cytoprotective agent
• Mitochondrial function support and anti-oxidative solution

• Hypersensitivity to any component
• Active ocular infection (bacterial, viral, fungal)
• Severe ocular surface damage or ulceration
• History of hypersensitivity to purine derivatives

• Use cautiously in autoimmune ocular diseases or severe dry eye.
• Avoid contamination of dropper tip to prevent infection.
• No black box warnings reported.
• Monitor for hypersensitivity signs: redness, swelling, itching, or pain.
• Discontinue if severe adverse effects occur.

Common:

• Mild eye irritation or burning
• Temporary blurred vision
• Mild conjunctival redness

Rare/Serious:

• Allergic conjunctivitis
• Corneal edema (rare with misuse)

• No significant systemic drug interactions expected.
• May cause additive irritation with other ophthalmic agents containing preservatives.
• No known interactions with food or alcohol.

• Increasing recognition in guidelines for mitochondrial support in ocular diseases.
• No major changes in indications or safety warnings in recent years.
• Emphasis on proper administration to avoid contamination and improve efficacy.

• Store at 15°C to 25°C (59°F to 77°F)
• Protect from light, heat, and freezing
• Keep container tightly closed
• Avoid high humidity
• Discard 28 days after opening
• Shake gently before use if suspension